Users Online: 1038
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
LETTER TO EDITOR
Year : 2013  |  Volume : 2  |  Issue : 1  |  Page : 13

Cost-utility analysis of using nimotuzumab in end-stage cancerous patient: Is it too expensive?


1 Maefahlaung University Hospital, Bangkok, Thailand
2 Hainan Medical University, China

Date of Web Publication11-Jan-2013

Correspondence Address:
Kamon Chaiyasit
Maefahlaung University Hospital, Bangkok
Thailand
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2278-330X.105873

Rights and Permissions

How to cite this article:
Chaiyasit K, Wiwanitkit V. Cost-utility analysis of using nimotuzumab in end-stage cancerous patient: Is it too expensive?. South Asian J Cancer 2013;2:13

How to cite this URL:
Chaiyasit K, Wiwanitkit V. Cost-utility analysis of using nimotuzumab in end-stage cancerous patient: Is it too expensive?. South Asian J Cancer [serial online] 2013 [cited 2019 Sep 15];2:13. Available from: http://journal.sajc.org/text.asp?2013/2/1/13/105873

Sir,

The use of new alternative cancer therapy for end-stage cancerous patient is interesting. Of several new agents, nimotuzumab is an immunological-based cancer therapeutic agent. Nimotuzumab is widely mentioned for its usefulness in management of end-stage cancerous patient. [1],[2] The prolongation of life expectation is mentioned as a usefulness of nimotuzumab administration. [3] However, the main concern is its high cost. Whether it is cost effectiveness is interesting. Here, the authors present the experience in using nimotuzumab in end-stage cancerous patients (about five cases). Based on our setting, the average cost for nimotuzumab management of the cancerous patient for a 3-month period is about 450,000 baht (about 15,000 USD) and the average extended life span is only about 1.5 months. It can be seen that the cost utility is about 10,000 USD/1 month life span extension. Of interest, the cost per utility is very expensive and this might not be better than no nimotuzumab in term of life expectation expansion (since the cases might have this prolonged life span without use of any drug). Although the new drug is effective but the great concern is on its high cost. The use of this drug has to be carefully considered on this fact.

 
  References Top

1.Li LF, Wang HQ, Liu XM, Zhang HL, Qiu LH, Qian ZZ, et al. Nimotuzumab in combination with chemotherapy in patients with advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 2011;33:626-8.  Back to cited text no. 1
[PUBMED]    
2.Bebb G, Smith C, Rorke S, Boland W, Nicacio L, Sukhoo R, et al. Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. Cancer Chemother Pharmacol 2011;67:837-45.  Back to cited text no. 2
[PUBMED]    
3.Saurez G, Cabanas R, Zaldívar M, Garnier T, Iglesias B, Piedra P, et al. Clinical experience with nimotuzumab in cuban pediatric patients with brain tumors, 2005 to 2007. MEDICC Rev 2009;11:27-33.  Back to cited text no. 3
    




 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
References

 Article Access Statistics
    Viewed1294    
    Printed57    
    Emailed0    
    PDF Downloaded215    
    Comments [Add]    

Recommend this journal